Podocyte dysfunction in atypical haemolytic uraemic syndrome

Nature Reviews Nephrology

Volumn 11, Issue 4, 2015, Pages 245-252

  Noris, Marina ^a   Mele, Caterina ^a   Remuzzi, Giuseppe ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT MEMBRANE ATTACK COMPLEX; DIACYLGLYCEROL KINASE; DIACYLGLYCEROL KINASE EPSILON; UNCLASSIFIED DRUG; COMPLEMENT;

CLINICAL FEATURE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT SYSTEM; DISEASE ASSOCIATION; GENE MUTATION; GENETIC DISORDER; GLOMERULONEPHRITIS; GLOMERULOPATHY; HEMOLYTIC UREMIC SYNDROME; HISTOPATHOLOGY; HUMAN; IMMUNE DYSREGULATION; INTRACELLULAR SIGNALING; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; NEPHROTIC SYNDROME; NONHUMAN; PATHOPHYSIOLOGY; PODOCYTE; PODOCYTE DYSFUNCTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEINURIA; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; ATYPICAL HEMOLYTIC UREMIC SYNDROME; GENETICS; MUTATION; PHYSIOLOGY;

ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT SYSTEM PROTEINS; DIACYLGLYCEROL KINASE; HUMANS; MUTATION; PODOCYTES;

EID: 84925620174     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2014.250     Document Type: Review

References (106)

1. Noris M. & Remuzzi G. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361, 1676-1687 (2009
2. Mele C., Remuzzi G. & Noris M. Hemolytic uremic syndrome. Semin. Immunopathol. 36, 399-420 (2014
3. Valoti E., et al. A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H dependent complement regulation. J. Am. Soc. Nephrol. http://dx.doi.org/10.1681/ASN.2013121339.
4. Dragon-Durey M. A., et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16, 555-563 (2005
5. Noris M., Mescia F. & Remuzzi G. STEC-HUS atypical HUS and TTP are all diseases of complement activation. Nat. Rev. Nephrol. 8, 622-633 (2012
6. Caprioli J., et al. Genetics of HUS: the impact of MCP CFH and IF mutations on clinical presentation response to treatment and outcome. Blood 108, 1267-1279 (2006
7. Noris M., et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. 5, 1844-1859 (2010
8. Legendre C. M., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 368, 2169-2181 (2013
9. Zuber J., et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am. J. Transplant. 12, 3337-3354 (2012
10. Lemaire M., et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat. Genet. 45, 531-536 (2013
11. Orth S. R. & Ritz E. The nephrotic syndrome. N. Engl. J. Med. 338, 1202-1211 (1998
12. Sanchez Chinchilla D., et al. Complement Mutations in diacylglycerol kinase epsilon-associated atypical hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. http://dx.doi.org/10.2215/CJN.01640214.
13. Westland R., et al. Phenotypic expansion of DGKE-associated diseases. J. Am. Soc. Nephrol. 25, 1408-1414 (2014
14. Remuzzi G. & Ruggenenti P. Thrombotic microangiopathies. in Renal Pathology (eds Tisher C. & Brenner B.) 1154-1184 (J. B. Lippincott 1994
15. Landau D., et al. Familial hemolytic uremic syndrome associated with complement factor H deficiency. J. Pediatr. 138, 412-417 (2001
16. Faul C., Asanuma K., Yanagida-Asanuma E., Kim K. & Mundel P. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol. 17, 428-437 (2007
17. Barisoni L., Schnaper H. W. & Kopp J. B. A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin. J. Am. Soc. Nephrol 2, 529-542 (2007
18. Ozaltin F., et al. DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J. Am. Soc. Nephrol. 24, 377-384 (2013
19. Rodriguez De Turco E. B., et al. Diacylglycerol kinase epsilon regulates seizure susceptibility and long-term potentiation through arachidonoyl- inositol lipid signaling. Proc. Natl Acad. Sci. USA 98, 4740-4745 (2001
20. Shulga Y. V., Topham M. K. & Epand R. M. Regulation and functions of diacylglycerol kinases. Chem. Rev. 111, 6186-6208 (2011
21. Lung M., et al. Diacylglycerol kinase epsilon is selective for both acyl chains of phosphatidic acid or diacylglycerol. J. Biol. Chem. 284, 31062-31073 (2009
22. Shulga Y. V., Topham M. K. & Epand R. M. Substrate specificity of diacylglycerol kinase-epsilon and the phosphatidylinositol cycle. FEBS Lett. 585, 4025-4028 (2011
23. Shulga Y. V., et al. Molecular species of phosphatidylinositol-cycle intermediates in the endoplasmic reticulum and plasma membrane. Biochemistry 49, 312-317 (2010
24. Rhee S. G. Regulation of phosphoinositide-specific phospholipase C. Annu. Rev. Biochem. 70, 281-312 (2001
25. Pettitt T. R., et al. Diacylglycerol and phosphatidate generated by phospholipases C and D, respectively have distinct fatty acid compositions and functions. Phospholipase D derived diacylglycerol does not activate protein kinase C in porcine aortic endothelial cells. J. Biol. Chem. 272, 17354-17359 (1997
26. Carew M. A., Paleolog E. M. & Pearson J. D. The roles of protein kinase C and intracellular Ca2+ in the secretion of von Willebrand factor from human vascular endothelial cells. Biochem. J. 286, 631-635 (1992
27. Ren S., Shatadal S. & Shen G. X. Protein kinase C beta mediates lipoprotein-induced generation of PAI 1 from vascular endothelial cells. Am. J. Physiol. Endocrinol. Metab. 278, E656-E662 (2000
28. Herbert J. M., Savi P., Laplace M. C., Dumas A. & Dol F. Chelerythrine a selective protein kinase C inhibitor counteracts pyrogen-induced expression of tissue factor without effect on thrombomodulin down-regulation in endothelial cells. Thromb. Res. 71, 487-493 (1993
29. Chakraborti T., Das S. & Chakraborti S. Proteolytic activation of protein kinase Calpha by peroxynitrite in stimulating cytosolic phospholipase A2 in pulmonary endothelium: involvement of a pertussis toxin sensitive protein. Biochemistry 44, 5246-5257 (2005
30. Garcia J. G., Stasek J., Natarajan V., Patterson C. E. & Dominguez J. Role of protein kinase C in the regulation of prostaglandin synthesis in human endothelium. Am. J. Respir. Cell. Mol. Biol. 6, 315-325 (1992
31. Gomez I., Foudi N., Longrois D. & Norel X. The role of prostaglandin E2 in human vascular inflammation. Prostaglandins Leukot. Essent. Fatty Acids 89, 55-63 (2013
32. Giannarelli C., Zafar M. U. & Badimon J. J. Prostanoid and TP receptors in atherothrombosis: is there a role for their antagonism?. Thromb. Haemost. 104, 949-954 (2010
33. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ. Res. 99, 1293-1304 (2006
34. Stegner D. & Nieswandt B. Platelet receptor signaling in thrombus formation. J. Mol. Med. (Berl.) 89, 109-121 (2011
35. Nunn D. L. & Watson S. P. A diacylglycerol kinase inhibitor R59022, potentiates secretion by and aggregation of thrombin-stimulated human platelets. Biochem. J. 243, 809-813 (1987
36. Hofmann T., et al. Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature 397, 259-263 (1999
37. Winn M. P., et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 308, 1801-1804 (2005
38. Moller C. C., et al. Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J. Am. Soc. Nephrol. 18, 29-36 (2007
39. Krall P., et al. Podocyte-specific overexpression of wild type or mutant trpc6 in mice is sufficient to cause glomerular disease. PLoS ONE 5, e12859 (2010
40. Marie J., et al. Hemolytic and uremic syndrome associated with an idiopathic nephrotic syndrome of 4 years' development [French]. Ann. Pediatr. (Paris) 16, 7-12 (1969
41. Zhang W., et al. Clinicopathological characteristics and outcome of Chinese patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a 9 year retrospective study. Nephron Clin. Pract. 112, c177-c183 (2009
42. Sinha R., AlAbbas A., Dionne J. M. & Hurley R. M. Simultaneous occurrence of atypical hemolytic uremic syndrome and acute lymphoblastic leukemia: a case report and literature review. Pediatr. Nephrol. 23, 835-839 (2008
43. Kimura M., et al. A patient with thrombotic microangiopathy accompanied by glomerular subendothelial electron dense deposits. Am. J. Nephrol. 18, 155-159 (1998
44. Izumi T., et al. An adult with acute poststreptococcal glomerulonephritis complicated by hemolytic uremic syndrome and nephrotic syndrome. Am. J. Kidney Dis. 46, e59-e63 (2005
45. Jha V., et al. Secondary membranoproliferative glomerulonephritis due to hemolytic uremic syndrome: an unusual presentation. Ren. Fail. 20, 845-850 (1998
46. Alsina Segui E., Martin Conde M. L., Craver Hospital L. & Fernandez Giraldez E. Postpartum hemolytic uremic syndrome: a rare entity and a treatment challenge [Spanish]. Nefrologia 28, 120-121 (2008
47. Nathanson S., Ulinski T., Fremeaux-Bacchi V. & Deschenes G. Secondary failure of plasma therapy in factor H deficiency. Pediatr. Nephrol. 21, 1769-1771 (2006
48. Sinha A., et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int. 85, 1151-1160 (2014
49. Sana G., et al. Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr. Nephrol. 29, 75-83 (2014
50. Noone D., et al. Successful treatment of DEAP-HUS with eculizumab. Pediatr. Nephrol. 29, 841-851 (2014
51. Green H., et al. Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab. Ren. Fail. 36, 1119-1121 (2014).
52. Cayci F. S., et al. Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation. Pediatr. Nephrol. 27, 2327-2331 (2012
53. University College London FH aHUS mutation database [online], www.fh-hus.org (2014).
54. Couser W. G. Mediation of immune glomerular injury. J. Am. Soc. Nephrol. 1, 13-29 (1990
55. Cybulsky A. V., Quigg R. J. & Salant D. J. Experimental membranous nephropathy redux. Am. J. Physiol. Renal Physiol. 289, F660-F671 (2005
56. Mathieson P. W. What has the immune system got against the glomerular podocyte?. Clin. Exp. Immunol. 134, 1-5 (2003
57. Torbohm I., et al. C5b 8 and C5b 9 modulate the collagen release of human glomerular epithelial cells. Kidney Int. 37, 1098-1104 (1990
58. Chen Z. H., et al. Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b 9 induced podocyte injury in vitro. Kidney Int. 77, 974-988 (2010
59. Pippin J. W., et al. DNA damage is a novel response to sublytic complement C5b 9 induced injury in podocytes. J. Clin. Invest. 111, 877-885 (2003
60. Ma, H., Sandor D. G. & Beck L. H. Jr. The role of complement in membranous nephropathy. Semin. Nephrol. 33, 531-542 (2013
61. Lin F., Emancipator S. N., Salant D. J. & Medof M. E. Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis. Lab. Invest. 82, 563-569 (2002
62. Alexander J. J., et al. Mouse podocyte complement factor H: the functional analog to human complement receptor 1. J. Am. Soc. Nephrol 18, 1157-1166 (2007
63. Lenderink A. M., et al. The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy. Am. J. Physiol. Renal Physiol. 293, F555-F564 (2007
64. Morita Y., et al. Complement activation products in the urine from proteinuric patients. J. Am. Soc. Nephrol. 11, 700-707 (2000
65. Onda K., et al. Excretion of complement proteins and its activation marker C5b 9 in IgA nephropathy in relation to renal function. BMC Nephrol. 12, 64 (2011
66. Endo M., et al. Glomerular deposition and urinary excretion of complement factor H in idiopathic membranous nephropathy. Nephron Clin. Pract. 97, c147-c153 (2004
67. Cybulsky A. V., Papillon J. & McTavish A. J. Complement activates phospholipases and protein kinases in glomerular epithelial cells. Kidney Int. 54, 360-372 (1998
68. Cybulsky A. V., Takano T., Papillon J. & McTavish A. J. Complement-induced phospholipase A2 activation in experimental membranous nephropathy. Kidney Int. 57, 1052-1062 (2000
69. Panesar M., Papillon J., McTavish A. J. & Cybulsky A. V. Activation of phospholipase A2 by complement C5b 9 in glomerular epithelial cells. J. Immunol. 159, 3584-3594 (1997
70. Takano T. & Cybulsky A. V. Complement C5b 9 mediated arachidonic acid metabolism in glomerular epithelial cells: role of cyclooxygenase 1 and 2. Am. J. Pathol. 156, 2091-2101 (2000
71. Takano T., et al. Inhibition of cyclooxygenases reduces complement-induced glomerular epithelial cell injury and proteinuria in passive Heymann nephritis. J. Pharmacol. Exp. Ther. 305, 240-249 (2003
72. Cybulsky A. V., et al. Complement C5b 9 membrane attack complex increases expression of endoplasmic reticulum stress proteins in glomerular epithelial cells. J. Biol. Chem. 277, 41342-41351 (2002
73. Cybulsky A. V., et al. The actin cytoskeleton facilitates complement-mediated activation of cytosolic phospholipase A2. Am. J. Physiol. Renal Physiol. 286, F466-F476 (2004
74. Manenti L., et al. Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrol. Dial. Transplant. 28, 2246-2259 (2013
75. Morita S., et al. Hemolytic uremic syndrome associated with immunoglobulin A nephropathy: a case report and review of cases of hemolytic uremic syndrome with glomerular disease. Intern. Med. 38, 495-499 (1999
76. Chang A., Kowalewska J., Smith K. D., Nicosia R. F. & Alpers C. E. A clinicopathologic study of thrombotic microangiopathy in the setting of IgA nephropathy. Clin. Nephrol. 66, 397-404 (2006
77. Krensky A. M., Ingelfinger J. R., Grupe W. E. & Rosen S. Hemolytic uremic syndrome and crescentic glomerulonephritis complicating childhood nephrosis. Clin. Nephrol. 19, 99-106 (1983
78. Siegler R. L., Brewer E. D. & Pysher T. J. Hemolytic uremic syndrome associated with glomerular disease. Am. J. Kidney Dis. 13, 144-147 (1989
79. Sherbotie J. R., et al. Hemolytic uremic syndrome associated with Denys-Drash syndrome. Pediatr. Nephrol. 14, 1092-1097 (2000
80. Chen G., Liu H. & Liu F. A glimpse of the glomerular milieu: from endothelial cell to thrombotic disease in nephrotic syndrome. Microvasc. Res. 89, 1-6 (2013
81. Tkaczyk M., Czupryniak A., Owczarek D., Lukamowicz J. & Nowicki M. Markers of endothelial dysfunction in children with idiopathic nephrotic syndrome. Am. J. Nephrol. 28, 197-202 (2008
82. Isome M., et al. Involvement of endothelial cell adhesion molecules in the development of anti Thy 1 nephritis. Exp. Nephrol. 10, 338-347 (2002
83. Gao C., et al. Procoagulant activity of erythrocytes and platelets through phosphatidylserine exposure and microparticles release in patients with nephrotic syndrome. Thromb. Haemost. 107, 681-689 (2012
84. Zoja C., et al. Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy. Am. J. Physiol. Renal Physiol. 303, F1370-F1381 (2012
85. Katavetin P. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 359, 205-206; author reply 206-207 (2008
86. Eremina V., et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358, 1129-1136 (2008
87. Amore A., et al. Aberrantly glycosylated IgA molecules downregulate the synthesis and secretion of vascular endothelial growth factor in human mesangial cells. Am. J. Kidney Dis. 36, 1242-1252 (2000
88. Qin W., et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1137-1143 (2011
89. Fogo A. B. & Kon V. The glomerulus-a view from the inside-the endothelial cell. Int. J. Biochem. Cell Biol. 42, 1388-1397 (2010
90. Wilkinson G. F., Purkiss J. R. & Boarder M. R. The regulation of aortic endothelial cells by purines and pyrimidines involves co-existing P2y-purinoceptors and nucleotide receptors linked to phospholipase C. Br. J. Pharmacol. 108, 689-693 (1993
91. Pueyo M. E., N'Diaye N. & Michel J. B. Angiotensin II elicited signal transduction via AT1 receptors in endothelial cells. Br. J. Pharmacol. 118, 79-84 (1996
92. Brock T. A. & Capasso E. A. Thrombin and histamine activate phospholipase C in human endothelial cells via a phorbol ester-sensitive pathway. J. Cell Physiol. 136, 54-62 (1988
93. Asselin J., et al. A collagen-like peptide stimulates tyrosine phosphorylation of syk and phospholipase C gamma2 in platelets independent of the integrin α2β1. Blood 89, 1235-1242 (1997
94. Keely P. J. & Parise L. V. The α2β1 integrin is a necessary co-receptor for collagen-induced activation of Syk and the subsequent phosphorylation of phospholipase Cγ2 in platelets. J. Biol. Chem. 271, 26668-26676 (1996
95. Bhagyalakshmi A., Berthiaume F., Reich K. M. & Frangos J. A. Fluid shear stress stimulates membrane phospholipid metabolism in cultured human endothelial cells. J. Vasc. Res. 29, 443-449 (1992
96. Anderson M., Roshanravan H., Khine J. & Dryer S. E. Angiotensin II activation of TRPC6 channels in rat podocytes requires generation of reactive oxygen species. J. Cell Physiol. 229, 434-442 (2014
97. Reiser J., Sever S. & Faul C. Signal transduction in podocytes-spotlight on receptor tyrosine kinases. Nat. Rev. Nephrol. 10, 104-115 (2014
98. Hong M., Sandor D. G. & Laurence H. B. The role of complement in membranous nephropathy. Semin. Nephrol. 33, 531-542 (2013
99. Pickering M. C., et al. C3 glomerulopathy: consensus report. Kidney Int. 84, 1079-1089 (2013
100. Wang Z., et al. NADPH oxidase-derived ROS contributes to upregulation of TRPC6 expression in puromycin aminonucleoside-induced podocyte injury. Cell Physiol. Biochem. 24, 619-626 (2009
101. Kim E. Y., Anderson M. & Dryer S. E. Insulin increases surface expression of TRPC6 channels in podocytes: role of NADPH oxidase and reactive oxygen species. Am. J. Physiol. Renal Physiol. 302, F298-F307 (2012
102. Cybulsky A. V., Papillon J. & McTavish A. J. Complement activates phospholipases and protein kinases in glomerular epithelial cells. Kidney Int. 54, 360-372 (1998
103. Ren G., Takano T., Papillon J. & Cybulsky A. V. Cytosolic phospholipases A(2)-α enhances induction of endoplasmic reticulum stress. Biochim. Biophys. Acta 1803, 468-481 (2010
104. Kim E. Y., Anderson M., Wilson C., Hagmann H., Benzing T. & Dryer S. E. NOX2 interacts with podocyte TRPC6 channels and contributes to their activation by diacylglycerol: essential role of podocin in formation of this complex: Am. J. Physiol. Cell Physiol. 305, C960-C971 (2013
105. Jiang L., et al. Over-expressing transient receptor potential cation channel 6 in podocytes induces cytoskeleton rearrangement through increases of intracellular Ca2+ and RhoA activation. Exp. Biol. Med. 236, 184-193 (2011
106. Bruneau S., et al. Loss of DGKe induces endothelial cell activation and death independently of complement activation. Blood http://dx.doi.org/10.1182/blood-2014-06-579953